<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:11539482;
mso-list-template-ids:-855237094;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:483667209;
mso-list-type:hybrid;
mso-list-template-ids:-1074252266 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l2
{mso-list-id:868183838;
mso-list-template-ids:1517742084;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1703744439;
mso-list-type:hybrid;
mso-list-template-ids:445917448 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdn.pfizer.com/pfizercom/2021-04/NCCN%20Pfizer%20Astellas%20Enzalutamide%20RFP_Final.pdf?VersionId=GTnTnMA95kPVrcLrxzuX4F8.y22TvjVp">NCCN/Pfizer/Astellas: Enzalutamide
in the Treatment of Prostate Cancer</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The overall aim is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment
of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. It is hoped proposals submitted in response to this RFP will guide development of enzalutamide and
its combination with other therapies. Studies with correlative endpoints will be accepted, and studies that retrospectively analyze biomarkers (tissue, liquid biopsy, and other approaches) within prospective trials or datasets will be accepted. The following
are selected priority areas to encourage the development of novel treatment approaches because of their ability to impact the unmet needs for patients with potentially lethal prostate cancer:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Earlier disease states<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Treatment and biology of oligometastatic disease<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Populations with unique vulnerabilities<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Innovative treatment strategies<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Specific disease settings in which enzalutamide may offer value<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Next generation imaging<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Biomarkers of enzalutamide response (including imaging)<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Strategies to improve the therapeutic index of enzalutamide<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due May 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: May 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-21-033.html">Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality
(UG3 / UH3 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this FOA is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy- related or associated morbidity
and mortality (PRAMM) in regions of the United States with high rates of maternal mortality. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 20, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: May 10.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-181.html">NINDS Program Project Grant (P01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose
to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant
is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for May 25, 2021 standard date: May 12.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-034.html">AAV Vector manufacturing for diseases affecting very small populations (R01) Clinical Trials Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Center for Biologics Evaluation and Research seeks to advance the development of gene therapies for diseases affecting very small populations, potentially even single individuals,
by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 28, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: May 17.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=332488">NIST Standards Services Curricula Development Cooperative Agreement Program (SSCD CAP)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIST Standards Services Curricula Development Cooperative Agreement Program (SSCD CAP) is seeking applications from eligible applicants to develop undergraduate and/or graduate level
curricula to incorporate documentary standards, standards development, and standardization information and content into seminars, modules, courses, and learning resources. The recipients will work with NIST to strengthen education and learning about documentary
standards, standards development, and standardization.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: May 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://fsucomgrants.wordpress.com/2021/04/15/academic-industrial-partnerships-for-translation-of-technologies-for-diagnosis-and-treatment-r01/Clinical%20Trial%20Optional">R01:
Clinical Trial Optional</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html">R01: Clinical Trial Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address
problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant
to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. These FOAs specify a partnership structure that is expected
to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance
to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial
organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise
translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These FOAs define “innovation” as likelihood to deliver a new capability to end users.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Research on Autism Spectrum Disorders (R03 / R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-199.html" target="_blank">R03</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-200.html" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-201.html" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and
optimal means of service delivery in relation to Autism Spectrum Disorders.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires March 6, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24; July 16, 2021 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 / R01 Clinical Trial Required)
<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-211.html" target="_blank">R34
</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions
that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden.
In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s)
that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness
of interventions to improve post-acute outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-210.html" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions
affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and
services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service
use) and intensity/burden for promoting optimal longer-term outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires March 17, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24; July 16, 2021 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/erp" target="_blank">Epilepsy Research Program</a><br>
<b>Idea Development Award</b><br>
Pre-application (required letter of intent): June 14. Full application: July 21.<br>
<b>Quality of Life Award</b><br>
Pre-application (required letter of intent): June 14. Full application: July 21.<br>
<b>Research Partnership Award</b><br>
Pre-application (required letter of intent): June 14. Full application: July 21.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: July 8.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://cdmrp.army.mil/funding/ocrp" target="_blank">Ovarian Cancer Research Program</a><br>
<b>Omics Consortium Award</b><br>
Pre-application (required letter of intent): June 24. Full application: July 8.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: June 24 (due to July 4 holiday).<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://cdmrp.army.mil/funding/prarp" target="_blank">Peer Reviewed Alzheimer’s Research Program</a><br>
<b>Convergence Science Research Award</b><br>
Pre-application (required letter of intent): June 14. Full application: July 21.<br>
<b>Innovation in Care and Support Award</b><br>
Pre-application (required letter of intent): June 14. Full application: July 21.<br>
<b>Research Partnership Award</b><br>
Pre-application (required letter of intent): June 14. Full application: July 21.<br>
<b>Accelerating Diagnostic Research Award</b><br>
Pre-application (required letter of intent): June 14. Full application: July 21.<br>
<b>Leveraging Approaches for Innovation in Care and Support Award</b><br>
Pre-application (required letter of intent): June 14. Full application: July 21.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: July 8.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://cdmrp.army.mil/funding/pcrp" target="_blank">Prostate Cancer Research Program</a><br>
<b>Early Investigator Research Award</b><br>
Pre-application (required letter of intent): June 17. Full application: July 1. Confidential letters of recommendation: July 7.<br>
<b>Physician Research Award</b><br>
Pre-application (required letter of intent): June 17. Full application: July 1. Confidential letters of recommendation: July 7.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: June 21.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Translational Science Award</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><br>
Pre-application (required letter of intent): July 15. Full application: July 29. <br>
<b>Health Disparity Research Award</b><br>
Pre-application (required letter of intent): July 15. Full application: July 29. <o:p>
</o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: July 16.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><br>
<b>Idea Development Award</b><br>
Pre-application (required letter of intent): September 2. Full application: September 23.
<br>
<b>Clinical Consortium Award</b><br>
Pre-application (required letter of intent): September 2. Full application: September 23.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: September 13.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Data Science Award</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><br>
Pre-application (required letter of intent): July 15. Full application: July 29. <br>
<b>Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award</b><br>
Pre-application (required letter of intent): July 15. Full application: July 29. <o:p>
</o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: July 19.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://cdmrp.army.mil/funding/scirp" target="_blank">Spinal Cord Injury Research Program</a><br>
<b>Clinical Trial Award</b><br>
Pre-application: May 24, 2021. Invited full application: September 3, 2021.<br>
<b>Translational Research Award</b><br>
Pre-application: May 24, 2021. Invited full application: September 3, 2021.<br>
<b>Investigator Initiated Research Award</b><br>
Pre-application: May 24, 2021. Invited full application: September 3, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: May 11.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://cdmrp.army.mil/funding/tscrp" target="_blank">Tuberous Sclerosis Complex Research Program</a><br>
<b>Exporation Hypothesis Development Award</b><br>
Pre-application (required letter of intent): June 17. Full application: July 8.<br>
<b>Idea Development Award</b><br>
Pre-application (required letter of intent): June 17. Full application: July 8<br>
<b>Clinical Translational Award</b><br>
Pre-application (required letter of intent): June 17. Full application: July 8.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: June 24 (due to July 4 holiday).<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdn.pfizer.com/pfizercom/2021-04/GMG_2021-RD-L_ATTR-CMResearchUS.pdf?VersionId=QexMsP6Qlge7jQW7.Qy3L1ea7ekSfswC">Pfizer: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Projects that will be considered for Pfizer support will focus on several or one specified area:
<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Early identification, evaluation, diagnosis, prognosis and treatment<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Study of hereditary ATTR genotypes and phenotypes:
<o:p></o:p></span></li><ul style="margin-top:0in" type="circle">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level2 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Non-Val30Met genotypes<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level2 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Val122Ile, Thr60Ala, Val30Met, and others<o:p></o:p></span></li></ul>
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy)<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l1 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Use of tafamidis in the clinical setting (i.e. real-world evidence)<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: May 26 (due to Memorial Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-213.html">Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic
disruption affects health-related outcomes, with close attention to underserved and vulnerable populations. To address these questions, this FOA aims to form a research consortium to access, extract, integrate, share, and analyze existing data from various
sources with broad population coverage including underserved and vulnerable populations. Examples of existing data include public health data; personal digital data; economic, labor, and commerce data; electronic health records (EHRs); claims data; and ongoing
health, demographic, and social surveys. This FOA solicits applications for individual population research projects that will be linked to a Social, Behavioral, and Economic Research on COVID-19 Consortium Coordination Center (SBECCC) to foster collaboration
and synergies across consortium member projects. Investigators will work with the SBECCC to enhance as well as share data resources used in proposed research both within the consortium as well as with others for health research purposes. The SBECCC will organize
annual meetings of the consortium investigators to share results, foster harmonization among measures collected, identify new opportunities for interaction/collaboration, and share results with NIH and the public. Further, the SBECCC will support the development
of reports and analyses summarizing and integrating the findings/products of the consortium.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 9, 2021 and November 8, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for June 9, 2021 due date: May 26 (due to Memorial Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 / R01 Clinical Trial not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-007.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-006.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements solicit applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement
in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven
significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable
costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI’s other technology development goals.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 25, 2021; March 1, 2022; and February 1, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for June 25, 2021 due date: June 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-015.html">Intramural – Extramural Collaboration for Drug Screening with Biofabricated 3-D Disease Tissue Models (UH2 /
UH3 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to promote partnerships between intramural investigators at the
<a href="https://ncats.nih.gov/bioprinting/work">NCATS 3-D Bioprinting Laboratory</a> and extramural researchers to jointly develop and demonstrate the use of 3-D biofabricated tissues for disease modeling and drug screening.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 28, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 15.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-037.html" target="_blank">3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its
<a href="https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative">
Beau Biden Cancer Moonshot Initiative</a><i> </i>invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon
Panel (BRP) as Recommendation I: <i>Generation of Human Tumor Atlases</i>. The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, humantumoratlas.org) via the implementation of three-dimensional
(3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans. Each project will lead to the multiplexed 3D characterization of at least one cancer transition investigated by the
HTAN (pre-malignant to malignant, primary to metastatic, therapy responsive to resistant). The data and analytical tools generated through this FOA will be made available for use by the research and clinical communities through the activities of the HTAN Data
Coordinating Center.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 30, 2021 and November 22, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for June 30, 2021 due date: June 17.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-size:12.0pt;font-family:Palatino;color:red">.</span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>